30 closest matches · ranked by relevance
Macrophage Activation Syndrome · Lymphohistiocytosis, Hemophagocytic · Arthritis, Juvenile
Primary: Incidence, Severity, Causality, and Outcomes of AEs (Serious and Nonserious) — 13; 6; 2; 10 Participants
Macrophage Activation Syndrome · Secondary Hemophagocytic Lymphohistiocytosis · Still Disease
Primary: Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab — 11; 4 Participants
NLRC4-MAS · XIAP Deficiency
Primary: Prevention of Flares — 2.71; NA Weeks
Hemophagocytic Lymphohistiocytosis
Primary: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) — 5040.638; 454.392 picogram/milliliter (pg/mL)
Hemophagocytic Syndrome (HPS)
Primary: Overall Survival at 2 Months — 6 Participants
Hemophagocytic Lymphohistiocytoses
Primary: Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10) — 2079.286; 15197.143 picogram/milliliter (pg/mL)
Asthma · Mastocytosis · Mast Cell Activation Syndrome
Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants
Primary Haemophagocytic Lymphohistiocytosis
Primary: Overall Response Rate (ORR) Second Line — 63.0 percentage of participants — p=0.0134
Thrombotic Microangiopathies · Hematologic Diseases
Primary: The Incidence of TA-TMA. — 5; 15 Participants
Thrombotic Microangiopathies · Atypical Hemolytic Uremic Syndrome · Multiple Organ Dysfunction Syndrome
Primary: Survival — 15 Participants — p=<0.0001
Juvenile Idiopathic Arthritis
Primary: Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever…
Hemophagocytic Lymphohistiocytosis
Primary: Overall Survival — 25 Participants
Primary Hemophagocytic Lymphohistiocytosis
Primary: Overall Response at Week 8 or End of Treatment (if Earlier) — 62.9; 50.0; 73.7 Percentage of participants — p=0.0053
Relapsing Remitting Multiple Sclerosis
Primary: ARMS (Assessing Relapses in Multiple Sclerosis) ADL Scores (Activities of Daily Living) — 3.1; 4.9 score on a scale — p=0.003
Pediatric Sepsis-induced MODS
Primary: Number of Subjects With Restoration of the TNF-alpha Response — 10; 8 Participants
Hemophagocytic Lymphohistiocytosis · Chronic Active Epstein-Barr Virus Infection · Chronic Granulomatous Disease
Primary: Percentage of Participants With Overall Survival (OS) — 80.4; 66.7 percentage of participants
Systemic Mastocytosis, Aggressive (ASM) · Leukemia, Mast Cell · Hematological Non-mast Cell Lineage Disease (AHNMD)
Primary: Subjects With Clinical Response [Partial Response (PR) + Complete Response (CR)] — 25 participants
Metabolic Syndrome X · Overweight · Hypertension
Primary: Insulin Sensitivity — .56; 0.55; 0.66; 0.70 % suppression inf rate 56 pmol/m2/min
Systemic Juvenile Idiopathic Arthritis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs by Severity, AEs Leading to Discontinuation, SAEs Leading to Discontinuation…
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Measurement of Effector T Helper Type 17 Cells in Peripheral Blood — 466.4; 432; 450; 759.8 spSFC/10^6 — p=0.003
Leukemia
Primary: Percentage of Participants With Overall Response Rate (ORR) — 59.6 Percentage of participants — p=<0.001
Drug Hypersensitivity
Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01
Acute Lymphoblastic Leukemia (ALL)
Primary: Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity…
Muckle Wells Syndrome
Primary: Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part) — 0; 81.3 percent of participants
MDS · Immunodeficiency · GATA2
Primary: Days to Neutrophil Engraftment — 12 Days
Inflammation · Familial Mediterranean Fever · Still's Disease, Adult-Onset
Primary: Mean Change in Daily Scores — -3.09 units on a scale
Rheumatoid Arthritis
Primary: Adverse Event (AE) Summary Over Time — 433; 390; 333; 294 Participants
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Any Adverse Events and Any Serious Adverse Events — 7; 0 participants
Kawasaki Disease
Primary: Number of Adverse Events (Focused on Side Effects From IVIG or Infliximab Administration) — 2; 3 events
TNF-receptor Associated Periodic Syndromes (TRAPS)
Primary: Percentage of Participants With Complete or Almost Complete Response at Day 15 — 95 Percentage of participants